Crossmark

Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial

Crossref DOI link: https://doi.org/10.1186/s12967-016-1107-2

Published Online: 2017-01-03

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Karpova, Darja

Bräuninger, Susanne

Wiercinska, Eliza

Krämer, Ariane

Stock, Belinda

Graff, Jochen

Martin, Hans

Wach, Achim

Escot, Christophe

Douglas, Garry

Romagnoli, Barbara

Chevalier, Eric

Dembowski, Klaus

Hooftman, Leon

Bonig, Halvard
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01841476 at ClinicalTrials.gov

Documents that mention this clinical trial

Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial
https://doi.org/10.1186/s12967-016-1107-2
License Information

Text and Data Mining valid from 2017-01-03

Version of Record valid from 2017-01-03
More Information

Article History

Received: 10 October 2016

Accepted: 8 December 2016

First Online: 3 January 2017

Document is current

Any future updates will be listed below